FMP
Nov 23, 2024 3:00 AM - Alex Lavoie(Last modified: Nov 25, 2024 10:04 AM)
Image credit: Google Images
ADMA Biologics, Inc. (NASDAQ:ADMA) is a biopharmaceutical company that focuses on developing, manufacturing, and marketing specialty plasma-derived biologics. These products are primarily used for the treatment of immune deficiencies and infectious diseases. ADMA operates in a competitive market alongside companies like Grifols and CSL Behring, which also specialize in plasma-derived therapies.
On November 22, 2024, Grossman Adam S, the director, officer, President, and CEO of ADMA, sold 48,967 shares of the company's common stock at $21.10 per share. This transaction was reported on Form 4, a document used by company insiders to report their transactions in company securities. Despite this sale, Grossman still holds 1,989,007 shares of ADMA's common stock.
ADMA is currently under investigation by The Schall Law Firm for potential securities fraud. The firm is looking into claims that ADMA may have made false and misleading statements to the market. This investigation could have significant implications for the company's stock and its investors, as highlighted by Accesswire. Investors who have incurred losses are encouraged to contact the law firm for further information.
Pomerantz LLP is also investigating ADMA for potential securities fraud. This follows the resignation of ADMA's independent outside auditor, CohnReznick LLP, on October 9, 2024. The announcement of the resignation led to a significant drop in ADMA's stock price, which fell by $3.32 per share, or 16.33%, closing at $17.01 on October 10, 2024. Pomerantz LLP is a leading firm in corporate, securities, and antitrust class litigation.
ADMA's financial metrics reveal a price-to-earnings (P/E) ratio of 72.92, indicating that investors are willing to pay $72.92 for every dollar of earnings. The company's price-to-sales ratio is 13.08, and its enterprise value to sales ratio is 13.14. ADMA's enterprise value to operating cash flow ratio is 58.47, and its earnings yield is 1.37%. The company has a debt-to-equity ratio of 0.44 and a strong current ratio of 7.09, indicating good short-term financial health.
May 14, 2024 11:41 AM - Sanzhi Kobzhan
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 24, 2024 9:30 AM - Rajnish Katharotiya
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...
May 27, 2024 3:30 PM - Rajnish Katharotiya
In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...